Interior of a relatively full Indonesian subway or train car.

The Adjuvant Investment Strategy

Adjuvant’s strategy aims to drive meaningful improvements in the public health of low- and middle-income countries while pursuing top-tier financial returns. Adjuvant’s focus areas include:

  • Neglected, high-burden, and emerging infectious diseases, including antimicrobial resistance and pandemic threats
  • Maternal, newborn, and child health challenges
  • Reproductive and sexual health
  • Nutrition

Adjuvant directs the majority of its investment activity to opportunities that have human efficacy signals from a phase II-or-later clinical trial or similar arm’s-length evaluations. We look for compelling proof-of-concept data to support our investment decisions.

A Commitment to Meaningful, Measurable Public Health Impact and SDG 3

As a signatory of the Operating Principles for Impact Management (the Impact Principles), Adjuvant Capital engaged BlueMark to undertake an independent verification of the alignment of Adjuvant Capital’s impact management system with the Impact Principles. Adjuvant Capital’s assets under management covered by the Impact Principles totals $300 million USD, for the period ending September 30, 2023. Our detailed BlueMark verification report can be found here.

Assets under management figure as reflected in Adjuvant Capital’s Disclosure Statement as of September 30, 2023. BlueMark’s assessment did not include verification of the AUM figure.

Any queries or concerns from external Adjuvant stakeholders may be directed to Adjuvant’s Chief Compliance Officer at [email protected].

Stay Updated

You can unsubscribe at any time using the link in the footer of our emails. View our privacy policy.